CN101735289B - Compounds extracted from traditional Chinese medicine of Cassia Seed and applications - Google Patents
Compounds extracted from traditional Chinese medicine of Cassia Seed and applications Download PDFInfo
- Publication number
- CN101735289B CN101735289B CN200810226864XA CN200810226864A CN101735289B CN 101735289 B CN101735289 B CN 101735289B CN 200810226864X A CN200810226864X A CN 200810226864XA CN 200810226864 A CN200810226864 A CN 200810226864A CN 101735289 B CN101735289 B CN 101735289B
- Authority
- CN
- China
- Prior art keywords
- compound
- chinese medicine
- applications
- traditional chinese
- cassia seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses two new compound structures from traditional Chinese medicine of Cassia Seed, which respectively are 1-hydroxyl-2-acetyl-3, 8-dimethoxy-6-O-[belta-D-apiofuranosyl-(1 to 2) beta-D-glucopyranosyl]-naphthalene (I) and 1-demethylaurantio-obtusin-2-O-beta-D-glucopyranoside (II). Meanwhile, the invention also discloses a method for extracting and separating the two new compounds, and applications of the derivates of the two compounds in preparing oxidation resistant medicines and liver medicines.
Description
Technical field
The present invention is a field of phytochemistry, and extraction, separation and the preparation technology field of pharmaceutically active ingredient in specifically belonging to relates in particular to the compounds and methods that from study of semen cassia extraction separation has pharmacologically active.
Background technology
Semen Cassiae (Semen Cassiae) is the dry mature seed of leguminous plants Cassia tora Cassia obtusifolia L. or little Cassia tora Cassia tora L..The chemical ingredients of Semen Cassiae is mainly anthraquinone component, also has other compositions such as Benzofurantone, sterols, fatty acid in addition.Modern pharmacology studies show that Semen Cassiae has hypotensive, and reducing blood-fat protects the liver and antibacterial isoreactivity, is widely used.In addition, Semen Cassiae is again the Chinese medicine that can be used as medicine-food two-purpose, is the good raw material of field of health care food.At present, deep not enough to the chemical constitution study of study of semen cassia, need further to excavate its effective constituent, the relation of clear and definite its pharmacologically active and effective constituent.
Summary of the invention
One of purpose of the present invention is the compound that is different from prior art that extraction separation has pharmacologically active from study of semen cassia, and extraction separation gets 2 new compounds and is:
1-hydroxyl-2-acetyl-3,8-dimethoxy-6-O-[β-D-apiofuranosyl-(1 → 2)-β-D-glucopyranosyl]-naphthalene (new naphthalene compounds, Compound I) and 1-demethylaurantio-obtusin-2-O-β-D-glucopyranoside (new anthraquinone analog compound, Compound I I).
The concrete extraction separation step of study of semen cassia is:
Semen Cassiae dry seed 20kg, pulverize the 95% alcohol diacolation extraction of back with 10 times of amounts of crude drug, be evaporated to and do not have the alcohol flavor, adding suitable quantity of water disperses, use sherwood oil, chloroform, n-butanol extraction successively, reclaim solvent and get petroleum ether extract 100g, chloroform extract 150g, n-BuOH extract 200g and remainder water part.The n-BuOH extract, separate through silica gel (100-200 order) column chromatography, the chloroform-methanol gradient elution, every 500ml collects first-class part, reclaims solvent, wherein 88-90 stream part, filter out the part that is insoluble to methyl alcohol, dried powder is Compound I I, wherein after part merging of 109-113 stream, separates through silica gel (100-200 order) column chromatography, ethyl acetate-methanol-water (10:2:1) wash-out, every 100ml collects portion stream part, obtains 74 flow points, wherein 22-33 stream part merging, all separate through polymeric amide (100-200 order) column chromatography, methanol-eluted fractions, the crystallization methanol wash of separating out gets Compound I.The extraction separation process as shown in Figure 1.
The compounds of this invention I is light yellow crystallization (methyl alcohol),
Nm:232,275,310 and 392, be the characteristic absorbance of naphthalene compounds.The thin layer plate spray shows red with 5%KOH.The Molish reaction is positive.HRESI-MS (m/z) provides quasi-molecular ion peak: 579.1684, and calculated value (C
25H
32O
14+ Na): 579.1679, so determine that its molecular formula is C
25H
32O
14
1H-NMR and
13The C-NMR data see the following form 1:
Table 1 Compound I NMR data (DMSO-d6, TMS, δ ppm)
By
1H-NMR,
13C-NMR and two-dimensional spectrum determine that compound structure is:
1-hydroxyl-2-acetyl-3，8-dimethoxy-6-O-[β-D-apiofuranosyl-(1→2)-β-D-glucopyranosyl]-naphthalene。
Compound I
The compounds of this invention II is the orange powder,
: 218,254,278,314 and 438, be the characteristic absorbance of anthraquinone analog compound.The thin layer plate spray shows red with 5%KOH.The Molish reaction is positive.HRESI-MS (m/z) provides quasi-molecular ion peak: 501.1003, and calculated value (C
25H
32O
14+ Na): 501.1024, so determine that its molecular formula is C
25H
32O
14
1H-NMR and
13The C-NMR data see the following form 2.
Table 2 Compound I I NMR data (DMSO-d
6, TMS, δ ppm)
By
1H-NMR,
13C-NMR and two-dimensional spectrum determine that compound structure is
1-demethylaurantio-obtusin-2-O-β-D-glucopyranoside。
Compound I I
Another purpose of purpose of the present invention, Compound I and Compound I I have purposes aspect the pharmacologically active medicine in preparation.Studies show that Compound I has the effect that the antagonism mouse carbon tetrachloride causes liver injury, prompting has liver-protecting activity, Compound I I has the effect of removing the DPPH free radical, and its activity obviously is better than vitamins C (Vitamin C, VC) (P＜0.01), prompting Compound I I has the activity of anti-oxidant aspect.
Embodiment
The extraction and separation method of embodiment 1 Compound I and II:
Semen Cassiae dry seed 20kg, pulverize the 95% alcohol diacolation extraction of back with 10 times of amounts of crude drug, be evaporated to and do not have the alcohol flavor, adding suitable quantity of water disperses, use sherwood oil, chloroform, n-butanol extraction successively, reclaim solvent and get petroleum ether extract 100g, chloroform extract 150g, n-BuOH extract 200g and remainder water part.The n-BuOH extract, separate through silica gel (100-200 order) column chromatography, the chloroform-methanol gradient elution, every 500ml collects first-class part, reclaims solvent, wherein 88-90 stream part, filter out the part that is insoluble to methyl alcohol, dried powder is Compound I I, wherein after part merging of 109-113 stream, separates through silica gel (100-200 order) column chromatography, ethyl acetate-methanol-water (10:2:1) wash-out, every 100ml collects portion stream part, obtains 74 flow points, wherein 22-33 stream part merging, all separate through polymeric amide (100-200 order) column chromatography, methanol-eluted fractions, the crystallization methanol wash of separating out gets Compound I.
The activity of embodiment 2 naphthalene compounds I aspect protecting the liver
1 experiment material
1.1 sample and reagent
Tetracol phenixin is provided by Beijing chemical reagent factory.Alanine aminotransferase (ALT), aspartate transaminase (AST) detection kit is built up biological study by Nanjing is provided.Positive control drug: Biphenylylmethylcarbinol, Dezhou Deyao Pharmaceutical Co., Ltd, lot number 040410.Specimen: the naphthalene compounds I:1-hydroxyl-2-acetyl-3 that above-mentioned separation obtains, 8-dimethoxy-6-O-[β-D-apiofuranosyl-(1 → 2)-β-D-glucopyranosyl]-naphthalene.
1.2 animal
Kunming mouse, male, body weight 18～22g is provided by Chinese department of Chinese medicine institute Experimental Animal Center.
1.3 instrument
752 ultraviolet grating spectrophotometers, Shanghai Precision Scientific Apparatus Co., Ltd; LDZ5-2 type whizzer, Beijing Medical Centrifugal Machine Factory; DKB-8A type electric heating constant temperature tank, the grand experimental installation of last Nereid company limited.
2 experiment contents
Get 90 of Kunming mouses, be divided into 9 groups at random, 10 every group.Grouping and gastric infusion dosage see Table 3, administration every day 1 time, 15d continuously.10h after the last administration, except that the blank group, all the other respectively organize abdominal injection 0.15% tetracol phenixin oil solution 10ml/kg, fasting, freely drink water.Behind the injection tetracol phenixin 16h, the mouse orbit venous plexus is got blood, the centrifugal 10min of 2500r/min, and separation of serum is in the content of 505nm mensuration mice serum ALT, AST.
3 experimental results
Large, medium and small 3 dosage groups all can significantly reduce the content that tetracol phenixin causes acute liver damage mice serum ALT and AST, with model group significant difference are arranged relatively, (P＜0.05 or P＜0.01).The results are shown in Table 3.
Table 3 Compound I to tetracol phenixin cause the chmice acute liver injury provide protection (x ± s, n=5)
Annotate: compare with model group,
*P＜0.05 or
*P＜0.01
Above presentation of results Compound I causes the chmice acute liver injury to tetracol phenixin and has significant protective effect under large, medium and small 3 dosage.
The activity of embodiment 3 anthraquinone analog compound II aspect anti-oxidant
1 experiment material
1.1 sample and reagent
DPPH (1, the bitter diazanyl free radical of 1-phenylbenzene-2-), Sigma company product.The positive control drug vitamins C, Sigma company.Specimen: the anthraquinone analog compound II that above-mentioned separation obtains is 1-demethylaurantio-obtusin-2-O-β-D-glucopyranoside
1.2 instrument
UV-T6 new millennium uv-spectrophotometric device, KQ-500E type ultrasonic cleaning machine for medical purpose (Kunshan Ultrasonic Instruments Co., Ltd.), Sartorius ten thousand/electronic balance.
2 experiment contents
2.1 remove the detection method of DPPH free radical
Respectively accurately claim to decide 2.1mgVC, 2.4mg Compound I I is dissolved in respectively and is mixed with concentration with ethanol in the 10mL measuring bottle and is respectively 0.21mg/mL, 0.24mg/mL, and it is standby above liquid to be measured to be diluted to series concentration by 2 times, 6 times, 18 times, 54 times, 162 times.Precision takes by weighing 8.4mgDPPH, is mixed with 0.084mg/mL (2.1 * 10
-4Mol/L) standby.
Accurate respectively each liquid 2ml to be measured that draws, the DPPH solution (0.084mg/mL) of adding 2mL shakes up the back and places 30min, is blank with the solvent, measures the Abs value A1 at 517nm place; Measure simultaneously above-mentioned liquid 2mL to be measured mix with the 2mL blank solvent back 517nm the Abs value be designated as A2; Measure again 2mLDPPH solution mix with the 2mL blank solvent back 517nm the Abs value be designated as A3; Be worth according to the clearance rate of following formula calculating three the DPPH free radical.
Clearance rate (%)=[1-(A1-A2)/A3] * 100%.
3 experimental results
Table 4 Compound I I and VC to the clearance rate of DPPH free radical (x ± s, n=5)
Annotate: * * represents P＜0.01
Above result shows: Compound I I has the effect of removing the DPPH free radical, and its activity obviously is better than VC (P＜0.01), and prompting Compound I I has the activity of anti-oxidant aspect.
Description of drawings
Fig. 1 is a Semen Cassiae medicinal material extraction separation schema
Claims (1)
1. the purposes of the naphthalene compounds with following Compound I structure in the anti-hepar damnification medicine of preparation:
Compound I
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810226864XA CN101735289B (en) | 2008-11-19 | 2008-11-19 | Compounds extracted from traditional Chinese medicine of Cassia Seed and applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810226864XA CN101735289B (en) | 2008-11-19 | 2008-11-19 | Compounds extracted from traditional Chinese medicine of Cassia Seed and applications |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110241694 Division CN102429917A (en) | 2008-11-19 | 2008-11-19 | Compounds extracted from Chinese herbal medicine semen cassiae and their application |
| CN 201110241695 Division CN102432650A (en) | 2008-11-19 | 2008-11-19 | Compounds extracted from Chinese medicine semen cassiae and application of compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101735289A CN101735289A (en) | 2010-06-16 |
| CN101735289B true CN101735289B (en) | 2011-12-21 |
Family
ID=42459363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810226864XA Expired - Fee Related CN101735289B (en) | 2008-11-19 | 2008-11-19 | Compounds extracted from traditional Chinese medicine of Cassia Seed and applications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101735289B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111072735A (en) * | 2019-12-20 | 2020-04-28 | 成都普思生物科技股份有限公司 | Anthraquinone compound extracted and separated from semen cassiae and method and application thereof |
-
2008
- 2008-11-19 CN CN200810226864XA patent/CN101735289B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Zhu Ju Wang等.Two new glycosides from the genus of Cassia.《Chinese Chemical Letters》.2007,第18卷(第10期),第1218-1220页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101735289A (en) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940687B (en) | A kind of Fructus Toosendan extract and uses thereof | |
| CN105111269A (en) | Novel limonin compound as well as preparation method and medical application thereof | |
| CN109912551A (en) | Sesquiterpene eudesmanolide class compound and its pharmaceutical composition and preparation method and application | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN104370871B (en) | The mouth diphenylene ketone oxide class separated from Swertia punicea Hemsl. and the application of suppression hepatitis B virus | |
| CN101112409A (en) | Preparation of phenolic acid valid target in dandelion and use thereof for inhibiting influenza virus | |
| CN101642450B (en) | New application of dicaffeoylquinic acid | |
| CN101057913B (en) | New medical use of vitex and method for preparing medicinal intermediate | |
| CN106008485A (en) | Medicinal composition of glimepiride, and application thereof in biomedicines | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN107056869B (en) | A kind of withanolide class compound and extracting method and application | |
| CN101735289B (en) | Compounds extracted from traditional Chinese medicine of Cassia Seed and applications | |
| CN102133220A (en) | Preparation method of pulsatilla saponin matter as well as preparation method of preparation thereof and application of pulsatilla saponin matter in preparing medicaments for treating cancers | |
| CN101766664B (en) | Detection method of total saponin of Radix Ilicis Asprellae | |
| CN105079011B (en) | A kind of preparation and application of the drug with antitumor action | |
| CN103735653A (en) | Traditional Chinese medicine extract with anti-tumor activity as well as preparation method and use thereof | |
| CN102898322B (en) | Compound and preparation method and application thereof | |
| CN102432650A (en) | Compounds extracted from Chinese medicine semen cassiae and application of compounds | |
| CN101156908A (en) | Alpha-glucosidase inhibitor- potentilla anserine extract as well as extracting method | |
| CN102429917A (en) | Compounds extracted from Chinese herbal medicine semen cassiae and their application | |
| CN101816702B (en) | Lung cancer preventing and treating composition extracted from selfheal and/or garden orache and application thereof in preparation of lung cancer preventing and treating medicine | |
| CN106619611B (en) | Application of eupatorium lactone in preparing medicine for resisting liver cancer and colon cancer | |
| CN105237604A (en) | New limonin compound, preparation method and medical uses thereof | |
| CN104546881A (en) | Application of degalactotigonin and derivative thereof in preparation of broad-spectrum antitumor medicine | |
| CN104523819B (en) | A kind of false indigo extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111221 Termination date: 20141119 |
|
| EXPY | Termination of patent right or utility model |